The company has successfully completed issuance of non convertible debentures (NCDs) aggregating to Rs 495 crore for cash at par on a private placement basis, Jubilant Life Sciences said in a regulatory filing.
The company is engaged in manufacturing and supply of active pharmaceutical ingredient (APIs), solid dosage formulations, radio pharmaceuticals, allergy therapy products and life science ingredients.
It also provides services in contract manufacturing of sterile injectables and ointments, creams and liquids and drug discovery and development.
Shares of Jubilant Life Sciences today ended at Rs 702.55per scrip on the BSE, down 0.95 per cent from previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content